Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug696 | CFTR Modulators Wiki | 0.47 |
| drug3967 | Tezacaftor/Ivacaftor + Ivacaftor Wiki | 0.33 |
| drug2450 | Mupirocin Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4461 | draw blood Wiki | 0.33 |
| drug4152 | Unsupervised exercise Wiki | 0.33 |
| drug4443 | convalescent plasma from recovered COVID 19 donor Wiki | 0.33 |
| drug698 | CGB-S-100 Wiki | 0.33 |
| drug4472 | electrolytes Wiki | 0.33 |
| drug4471 | efgartigimod PH20 SC Wiki | 0.33 |
| drug4585 | modified IPAC-UHN PPE Wiki | 0.33 |
| drug2401 | Minocycline Wiki | 0.33 |
| drug4470 | efgartigimod IV Wiki | 0.33 |
| drug1408 | Environmental Decontamination Wiki | 0.33 |
| drug4456 | diagnostic Wiki | 0.33 |
| drug903 | Chlorhexidine Gluconate Wiki | 0.33 |
| drug4449 | current IPAC-UHN PPE Wiki | 0.33 |
| drug4453 | data record Wiki | 0.33 |
| drug2275 | Magnetic Resonance Imaging (MRI) Wiki | 0.33 |
| drug3472 | SELF-BREATHE Wiki | 0.33 |
| drug4094 | Trimethoprim Sulfamethoxazole (TMP/SMX) Wiki | 0.33 |
| drug2935 | Placebo Comparator Wiki | 0.24 |
| drug502 | Bacille Calmette-Guérin (BCG) Wiki | 0.24 |
| drug1993 | Interview Wiki | 0.19 |
| drug1436 | Exercise Wiki | 0.19 |
| drug2981 | Placebo oral tablet Wiki | 0.06 |
| drug3192 | Questionnaire Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005355 | Fibrosis NIH | 0.47 |
| D055732 | Pulmonary Aspergillosis NIH | 0.33 |
| D001228 | Aspergillosis NIH | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001229 | Aspergillosis, Allergic Bronchopulmonary NIH | 0.33 |
| D009181 | Mycoses NIH | 0.24 |
| D017093 | Liver Failure NIH | 0.24 |
| D000755 | Anemia, Sickle Cell NIH | 0.17 |
| D001987 | Bronchiectasis NIH | 0.15 |
| D004417 | Dyspnea NIH | 0.10 |
| D017563 | Lung Diseases, Interstitial NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.07 |
| D003141 | Communicable Diseases NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001399 | Hepatic failure HPO | 0.24 |
| HP:0002110 | Bronchiectasis HPO | 0.15 |
| HP:0002098 | Respiratory distress HPO | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006515 | Interstitial pneumonitis HPO | 0.09 |
| HP:0002088 | Abnormal lung morphology HPO | 0.07 |
Navigate: Correlations HPO
There are 9 clinical trials
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
Description: Descriptive summary with corresponding 95% confidence interval.
Measure: Proportion of STAR-TER subjects with a negative MRSA culture at Day 28 vs. observational arm of historic STAR-Too trial Time: Day 28Description: Pulmonary exacerbation is defined as having 1 of the major criteria or 2 minor signs/symptoms and fulfillment of symptom duration. Major criteria: Absolute decrease in FEV1 of ≥ 10% from Visit 1 (Baseline), unresponsive to albuterol (in participants able to reproducibly perform spirometry) Oxygen saturation <90% on room air or absolute decrease of ≥ 5% from Visit 1 New lobar infiltrate(s) or atelectasis on chest radiograph Hemoptysis (more than streaks on more than one occasion in past week) Minor signs/symptoms: Increased work of breathing or respiratory rate New or increased adventitial sounds on lung exam Weight loss ≥5% of body weight or decrease across 1 major percentile in weight percentile for age in past 6 months Increased cough Decreased exercise tolerance or level of activity Increased chest congestion or change in sputum Signs/symptoms duration: initial symptom must have occurred for at least 5 days.
Measure: Proportion of subjects with a protocol-defined pulmonary exacerbation between Baseline and Day 28 treated with antibiotics active against MRSA Time: Period ranging from start of Baseline and continuing through Day 28Description: Pulmonary exacerbation is defined as having 1 of the major criteria or 2 of the minor signs/symptoms and fulfillment of symptom duration. Major criteria: Absolute decrease in FEV1 of ≥ 10% from Visit 1 (Baseline), unresponsive to albuterol (in participants able to reproducibly perform spirometry) Oxygen saturation <90% on room air or absolute decrease of ≥ 5% from Visit 1 New lobar infiltrate(s) or atelectasis on chest radiograph Hemoptysis (more than streaks on more than one occasion in past week) Minor signs/symptoms: Increased work of breathing or respiratory rate New or increased adventitial sounds on lung exam Weight loss ≥5% of body weight or decrease across 1 major percentile in weight percentile for age in past 6 months Increased cough Decreased exercise tolerance or level of activity Increased chest congestion or change in sputum Signs/symptoms duration: initial symptom must have occurred for at least 5 days.
Measure: Proportion of subjects with a protocol-defined pulmonary exacerbation between Baseline and Day 28 treated with any oral, inhaled, or IV antibiotics regardless of potential activity against MRSA Time: Period ranging from start of Baseline and continuing through Day 28Description: Pulmonary exacerbation is defined as having 1 of the major criteria or 2 of the minor signs/symptoms and fulfillment of symptom duration. Major criteria: Absolute decrease in FEV1 of ≥ 10% from Visit 1 (Baseline), unresponsive to albuterol (in participants able to reproducibly perform spirometry) Oxygen saturation <90% on room air or absolute decrease of ≥ 5% from Visit 1 New lobar infiltrate(s) or atelectasis on chest radiograph Hemoptysis (more than streaks on more than one occasion in past week) Minor signs/symptoms: Increased work of breathing or respiratory rate New or increased adventitial sounds on lung exam Weight loss ≥5% of body weight or decrease across 1 major percentile in weight percentile for age in past 6 months Increased cough Decreased exercise tolerance or level of activity Increased chest congestion or change in sputum Signs/symptoms duration: initial symptom must have occurred for at least 5 days.
Measure: Time to protocol-defined pulmonary exacerbation over the six-month study Time: Period ranging from start of Baseline and continuing through Month 6Description: Pulmonary exacerbation is defined as having 1 of the major criteria or 2 of the minor signs/symptoms and fulfillment of symptom duration. Major criteria: Absolute decrease in FEV1 of ≥ 10% from Visit 1 (Baseline), unresponsive to albuterol (in participants able to reproducibly perform spirometry) Oxygen saturation <90% on room air or absolute decrease of ≥ 5% from Visit 1 New lobar infiltrate(s) or atelectasis on chest radiograph Hemoptysis (more than streaks on more than one occasion in past week) Minor signs/symptoms: Increased work of breathing or respiratory rate New or increased adventitial sounds on lung exam Weight loss ≥5% of body weight or decrease across 1 major percentile in weight percentile for age in past 6 months Increased cough Decreased exercise tolerance or level of activity Increased chest congestion or change in sputum Signs/symptoms duration: initial symptom must have occurred for at least 5 days.
Measure: Number of protocol-defined pulmonary exacerbations over the six-month study Time: Period ranging from start of Baseline and continuing through Month 6Description: Proportion of subjects with a negative culture for MRSA at Day 56
Measure: MRSA Culture Status Time: Day 56Description: Compliance refers to the amount of prescribed medication consumed.
Measure: Proportion of subjects with >80% compliance for study drug during the first 28 days Time: Day 28People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in 10 people with CF must take medication to assist their digestion. In spite of this, complications such as bowel blockage occur. Finding out how already licenced drugs for CF work in the gut is the first step in repurposing medications. Tezacaftor/Ivacaftor with Ivacaftor is a drug combination which corrects the basic defect in CF an has shown improvements on lung function. The purpose of this study is to evaluate, using Magnetic Resonance Imaging (MRI) and patient-reported outcomes, whether Tezacaftor/Ivacaftor with Ivacaftor has an effect on improving gastrointestinal problems in CF.
Description: Time taken after eating for ingested food to be identifiable at the caecum on MRI
Measure: Oro-caecal Transit Time Time: 1 day of scanningDescription: Volume of stomach at each time point of digestion to measure gastric emptying time
Measure: Gastric volume Time: 1 day of scanningDescription: Volume of water content in small bowel representing secretions and post prandial change in small bowel water content at T240 and T300
Measure: Small bowel water content (corrected for body surface area) Time: 1 day of scanningDescription: Volume of colon representing ease of chyme passage through colon
Measure: Colonic volume (corrected for body surface area) Time: 1 day of scanningDescription: Gastrointestinal symptoms measured by patient reported outcomes to monitor relationships with outcomes measure by MRI
Measure: Gastrointestinal symptoms Time: 1 day of scanningDescription: Volume of sigmoid colon
Measure: Sigmoid colon volume Time: 1 day of scanningDescription: An approximate measure of water content in chyme present in the ascending colon
Measure: T1 relaxation of ascending colon chyme Time: 1 day of scanningDescription: A measure of fat content in chyme present in the ascending colon
Measure: Fat fraction of ascending colon chyme Time: 1 day of scanningDescription: A measure of elastase in stool to evaluate pancreatic function
Measure: Faecal elastase Time: 1 dayDescription: A measure of microbiome in sputum and stool
Measure: Sputum and faecal microbiome Time: 1 dayDescription: A measure of intestinal inflammation
Measure: Faecal calprotectin Time: 1 dayDescription: A measure of motility at the terminal ileum using the GIQuant tool in arbitrary units
Measure: Terminal Ileum motility Time: 1 dayThis study aims to assess the effects of programmed exercise combined with CFTR protein modulator drugs in the cardiorespiratory fitness, strength, functional capacity and agility in a group of young patients with Cystic Fibrosis.
Description: Changes in strength will be measured using a five repetition maximum test (5RM)
Measure: Change in Strength Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in cardiorespiratory fitness will be measured using a cardiopulmonary exercise test (CPET)
Measure: Change in Cardiorespiratory Fitness Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in FEV1 will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)
Measure: Changes in Forced expiratory volume in 1 second (FEV1) Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in FVC will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)
Measure: Changes in Forced vital capacity (FVC) Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in FEV1/FVC ratio (FEV1%) will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)
Measure: Changes in FEV1/FVC ratio (FEV1%) Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in FEF will be measured using Spirometry (z-score based on Global Lung Function Initiative reference DOI: 10.1016/j.arbres.2017.07.019)
Measure: Changes in Forced expiratory flow (FEF) Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in physical activity levels will be measured using PAQ-C for children under 14 years of age and PAQ-A for adolescents over 14 years of age. Items 1 to 9 will be used in the physical activity composite score, and means will be calculated to obtain the final PAQ-C activity summary score. Items 1 to 8 will be used in the physical activity composite score, and means will be calculated to obtain the final PAQ-A activity summary score. A score of 1 indicates low physical activity, whereas a score of 5 indicates high physical activity.
Measure: Changes in Physical Activity Questionnaire (PAQ) for children and adolescents Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Changes in quality of life will be measures with the Cystic Fibrosis-Questionnaire-Revised (CFQ-R). Scores for each health related quality of life domain are calculated; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.
Measure: Change in quality of life: Cystic Fibrosis-Questionnaire-Revised (CFQ-R) Time: Four assessment points throughout the study: baseline and after each 8-week interventionDescription: Chloride concentration in sweat (mEq/L) will be measured in the laboratory using an MK II Chloride Analyzer 926S
Measure: Sweat chloride level Time: Four assessment points throughout the study: baseline and after each 8-week interventionImpacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic
Description: Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical),
Measure: Cancellation or postponement of consultations by the health professional or patient, Time: Up to 6 monthsDescription: Number of consultations cancelled by the teleconsultation/replacement patient,
Measure: Patient cancellation of teleconsultations/telecare replacement, Time: Up to 6 monthsDescription: Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled)
Measure: Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled), Time: Up to 6 monthsDescription: Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration).
Measure: Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration). Time: Up to 6 monthsDescription: Cancellation or postponement by the patient of consultations (medical or paramedical) Patient cancellation of teleconsultations/telecare proposed by the health professional Cancellation or postponement by the patient of hospitalizations (acute or scheduled)
Measure: The reduction of each of the elements of care provision and health care utilization: Time: Up to 6 monthsDescription: Intravenous instead of intravenous administration
Measure: The change of modality of administration of antibiotic cures Time: Up to 6 monthsDescription: Questionnaire about taking or not taking treatment during confinement
Measure: Compliance Time: Up to 6 monthsDescription: Scale 0-21
Measure: Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well) Time: Up to 6 monthsDescription: A questionnaire on the presence or absence of toxic consumption
Measure: Presence or absence of toxic consumption (drug, alcohol) during the lockdown Time: Up to 6 monthsDescription: Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods)
Measure: Evaluation of the knowledge, experience and social representations of the risk of Covid-19 Time: Up to 6 monthsDescription: Role of social inequalities in the consequences of containment assessed by qualitative methods
Measure: Assessing the role of social inequalities in the consequences of lockdown Time: Up to 6 monthsDescription: Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis
Measure: Suspected and/or confirmed Covid-19 in patients with cystic fibrosis. Time: Up to 6 monthsThis study is investigating the role of allergic (Th2) inflammation in patients with Cystic Fibrosis (CF) and history of fungal infection and/or Allergic Bronchopulmonary Aspergillosis. Little is known about fungal infection in CF and conflicting results exist on whether this results in worse lung function over time. There is concern that persistent fungal infection can result in worse clinical outcome measures in patients with CF. Also, it is unclear how ABPA develops, but may be related to the amount of fungus a patient with CF is infected with. This study looks at inflammatory patterns and allergic responses to fungal elements to help identify biomarkers and signs of allergic disease in fungally infected patients with CF.
Description: Difference in sputum Th2 biomarkers (ECP, IL4, IL5, IL10, IL13, and eosinophil count) in patients with CF with fungal infection with expected elevation of sputum Th2 biomarkers in patients with CF and ABPA compared to those without fungal infection and without ABPA.
Measure: Difference in Th2 Sputum Markers Time: Day 1Description: Serum Th2 biomarkers in patients with fungal infection and ABPA (Table 3). Serum Th1 biomarkers in patients with fungal infection and ABPA (Table 3). Serum sensitization markers to fungal allergens in patients with fungal infection and ABPA (Table 4). Baseline and historic lung function, historical comorbid diagnoses and BMI measurements in patients with fungal infection and ABPA. Environmental factors that are possibly related to fungal infection and ABPA in patients with CF. Immune profile: A profile of each group will be based upon their findings of each set of biomarkers: Th1, Th2, mold allergy panel, and systemic markers of inflammation. Based upon findings in each of these categories (elevated, depressed), we will be able to formulate a profile based upon the type of marker/inflammatory pathway.
Measure: Other markers of fungal inflammation and allergic reaction in patients with CF Time: Day 1Description: Banking of both sputum and serum to potentially utilize microbiome and transcriptome techniques for further immunotyping and infection characterization.
Measure: Biobanking of specimens Time: Day 1A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
Description: The number of patients recruited into this study over a 12-month period
Measure: Feasibility: the number of patients recruited into this study over a 12-month period Time: 12 monthsThe purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on expanded nasal cells at Cincinnati Children's Human Nasal Epithelium (HNE) Core Laboratory. The results will be confirmed and translated into bedside care through an N of 1 trial to determine effectiveness of treatment.
Description: Absolute change in ppFEV1 of 5% or greater
Measure: ppFEV1 Time: 16 weeksAn observational study of patients with cystic fibrosis (CF) starting treatment with Kaftrio (Elexacaftor / Tezacaftor / Ivacaftor) as part of routine clinical care, following EMA licensing (approved end of Aug 2020). - Patients with CF who are p.Phe508del homozygotes will already be receiving the less effective CFTR modulator drug Symkevi (Tezacaftor / Ivacaftor) and will switch to KaftrioTM. - Patients who are who are compound heterozygotes for p.Phe508del / minimal function mutation currently have access to no effective CFTR modulator and will be starting a CFTR modulator (Kaftrio) for the first time. Participants attend a study visit before Kaftrio treatment commences, followed by visits at 12 and 24 weeks after starting treatment. At each visit they will be scanned before and after standardised meals in the morning and mid-day (11 scans in total over 6 hours). No intravenous contrast or bowel preparation will be used. Participants will complete questionnaires on gastrointestinal symptoms as well as providing stool and sputum samples for assessment of microbiome and stool for inflammatory mediators and pancreatic function (elastase).
Description: the time when the test meal is first detectable in the caecum
Measure: Difference in oro-caecal transit time (OCTT) in minutes at baseline and 24 weeks Time: 3 days of scanningDescription: A measure of small bowel water representing secretions
Measure: Small bowel water content (SBWC) area under the curve (AUC), corrected for body surface area, measured in L.min/m^2 between 0 and 360 minutes at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: These are small bowel water measurements before and after the second test meal
Measure: Change in SBWC between 240 and 300 minutes (delta DTI) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: volume of colon representing ease of chyme passage through colon
Measure: Colonic volume area under the curve (AUC), corrected for body surface area at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of gut inflammation
Measure: Stool calprotectin at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of types of microbiome present in the stool and sputum
Measure: Stool and sputum microbiome at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A marker of pancreatic exocrine function
Measure: Stool elastase at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of motility at the terminal ileum using the GIQuant tool in arbitrary units
Measure: Terminal ileum motility at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by the CFAbd-Score Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by the PAC-SYM score Time: 3 days of scanningDescription: A measure of gut symptoms over the preceding 2 weeks and during the study day
Measure: Abdominal symptoms as measured by 3 domains from the Gastrointestinal Symptoms Rating Scale (GSRS) Time: 3 days of scanningDescription: A measure of lung function
Measure: Spirometry (FEV1) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of body mass
Measure: Weight (kg) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningDescription: A measure of growth
Measure: Height (m) at baseline, 12 weeks and 24 weeks Time: 3 days of scanningCystic fibrosis (CF) affects men and women equally, but after the onset of puberty, women with CF have a lower life expectancy than men with CF. Despite these known differences, the link between CF symptom trends and the menstrual cycle remains critically understudied. To address this gap, this study will investigate changes in CF-specific symptoms among women with CF to evaluate whether and how they correlate with their menstrual cycle. Specifically, the investigators hope to examine whether CF-related symptoms change throughout the menstrual cycle, what the impact of those symptoms is on quality of life, and how feasible it is to use a period tracking app to track CF-related symptoms throughout the menstrual cycle. Investigators are asking women ages 18-45 with CF, who have regular menstrual cycles, to participate. Study procedures, including online surveys, period tracking, and interview, will take approximately 3 months.
Description: Rating of Mild, Moderate, or Severe in the Clue smartphone app
Measure: Average change of Cystic Fibrosis-related pulmonary symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal) Time: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollmentDescription: Rating of Mild, Moderate, or Severe in the Clue smartphone app
Measure: Average change of Cystic Fibrosis-related sinus symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal) Time: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollmentDescription: Rating of Mild, Moderate, or Severe in the Clue smartphone app
Measure: Average change of Cystic Fibrosis-related rheumatic symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal) Time: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollmentDescription: Rating of Mild, Moderate, or Severe in the Clue smartphone app
Measure: Average change of Cystic Fibrosis-related gastrointestinal symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal) Time: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports